New data shows apremilast helps psoriatic arthritis patients over two years
NCT ID NCT03106051
First seen Sep 30, 2025 · Last updated May 04, 2026 · Updated 25 times
Summary
This study followed about 526 adults with active psoriatic arthritis who were already prescribed apremilast (Otezla) by their doctor. Researchers tracked how many patients saw at least a 1-point improvement on a 0-4 doctor-rated skin and joint scale after 6 months, and continued monitoring for up to 100 weeks. The goal was to see how well the drug works in real-world, long-term use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHRITIS, PSORIATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Klinikum Stephansplatz
Hamburg, 20354, Germany
-
Rheumatology at Struenseehaus
Altona, Free and Hanseatic City of Hamburg, 22767, Germany
Conditions
Explore the condition pages connected to this study.